BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Last trade$97.40
Day change+$1.09 (+1.13%)
Day range$94.18 – $101.12
Volume532,959
Market cap$4.60B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.6B
Price / earnings
100.14×
Price / book
8.12×
Price / sales
10.53×
EV / sales
9.45×
EV / EBITDA
79.54×
Profitability
Earnings per share
$0.96
Return on assets
6.04%
Return on equity
8.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.16×
Current ratio
11.25×
Quick ratio
10.89×
Cash ratio
9.26×
Cash flow
Price / cash flow
96.05×
Price / free cash flow
135.72×
Free cash flow
$33.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BLLN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Revenue
$122.98M
$109.45M
$108.39M
$96.05M
Cost of revenue
$35.84M
$32.34M
$29.29M
$27.45M
Gross profit
$87.15M
$77.11M
$79.1M
$68.6M
Selling, general and administrative
$55.91M
$54.29M
$46.57M
$44.02M
Research and development
$20.22M
$17.32M
$14.69M
$14.25M
Total operating expenses
$76.12M
$71.6M
$61.26M
$58.27M
Operating income
$11.02M
$5.5M
$17.83M
$10.33M
Interest expense
-$6K
-$8K
-$10K
-$3K
Income before taxes
$17.39M
$7.52M
$18.51M
$6.3M
Income taxes
$1.3K
-$536K
$539K
$320K
Net income
$17.39M
$8.05M
$17.97M
$5.98M
Net income attributable to common shareholders
$17.39M
$8.05M
$17.97M
$2.53M
EBITDA
$13M
$7.33M
$19.57M
$12.01M
Basic earnings per share
$0.37
$0.17
$0.39
$0.08
Diluted earnings per share
$0.32
$0.15
$0.34
$0.05
Recent news
Company coverage with links to the original publishers.
BillionToOne raised 2026 revenue guidance to $460-470 million with Q3 revenue up 47% year-over-year to $123 million. The company achieved its fifth consecutive quarter of GAAP profitability while maintaining 71% gross margins. Key developments include the December 15 launch of Northstar Clear, a tissue-free blood test for cancer detection, and demonstrated superior performance of its Northstar Response test compared to tissue-dependent competitors.
BillionToOne (BLLN) reported Q3 2026 revenue of $122.98 million, up 47.3% year-over-year, beating consensus estimates by 5.81%. EPS of $0.32 doubled analyst expectations. The company delivered 206,000 tests with an average selling price of $589. However, the stock carries a Zacks Rank #4 (Sell) rating despite recent outperformance.
BillionToOne (BLLN) is set to report Q3 2026 earnings on November 4, with Wall Street expecting 60% YoY EPS growth to $0.16 and 39.2% revenue growth to $116.23 million. However, the stock carries a negative Earnings ESP of -3.23% and a Zacks Rank #4 (Sell), making it unlikely to beat consensus estimates. The company has beaten EPS estimates only twice in the last four quarters.
David Tsao, co-founder and CTO of BillionToOne, sold 10,000 shares for $1 million on August 25, 2026, through a pre-planned Rule 10b5-1 trading arrangement. The sale occurred after the stock declined from a 52-week high of $150.44, but Tsao retains 580,000 stock options, maintaining significant equity alignment with the company. Despite the recent share price drop following Q2 earnings, BillionToOne reported strong 64% year-over-year revenue growth.
BillionToOne, a molecular diagnostics company, successfully completed its initial public offering (IPO) on the Nasdaq Global Select Market, raising approximately $314.0 million by selling 5,233,765 shares of Class A common stock at $60.00 per share.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.